Videos

“So, the concept behind delivering something orally in a spray is to hopefully avoid the whole GI effect and get faster absorption,” says Steven A. Kaplan, MD.

"We had a really clear idea...[We were looking at] how we can better optimize the system for cleaning," says Ana Lidia Flores-Mireles, PhD.

The panel outlines combination therapy options for patients with advanced prostate cancer and discusses the potential benefits of intensification of androgen deprivation therapy.

“I think the future is very bright for endourology and pushing the envelope with different minimally invasive techniques to remove stones,” says Marcelino E. Rivera, MD.

Experts on prostate cancer discuss factors to consider while making treatment decisions for patients with nonmetastatic castration-sensitive prostate cancer.

“Within our department at University of Michigan, there has been increased numbers of vasectomy procedure days to be able to meet the demand so that there's not a very long prolonged delay for our patients,” says Catherine S. Nam, MD.

"We've really found that [same-day discharge is] a reasonable option and something that many patients are really pleased by," says Brian R. Lane, MD, PhD, FACS.

Experts discuss the patient quantity and qualifications for the CORE-001 trial.

Experts give an overview of the ASCO 2024 data.

“We need formal recommendations for nonopioid pain management strategies and medications,” says Laura Gressler, MS, PhD.

“The hope is that the research and technology will be mature enough at the time that they're ready to use that tissue for a biological child,” says Amanda J. Saraf, DO.

"What we think is really nice about it is it's not required to have it into an electronic medical record for this to work on the wards," says Jennifer Ann Meddings, MD.

“It will be interesting to see how this plays out long-term in the changing political scheme, as well as the general trend of the current generation potentially having different thoughts in terms of wanting to have children or not in the future,” says Catherine S. Nam, MD.

“We believe this is going to be the next rendition of how we can train physicians, as well as make surgeons more effective at their job,” says Nitin K. Yerram, MD.

"If we want to do a targeted therapy, we have to know exactly where and what we are treating," says Gamal M. Ghoniem, MD, FACS, ABU/FPMRS.

The key opinion leaders explore the challenges and limitations associated with using prostate-specific antigen (PSA) as a biomarker for prostate cancer detection and monitoring.

The panel of experts in prostate cancer offers a comprehensive overview of prostate cancer diagnosis, emphasizing the role of prostate-specific antigen (PSA) testing in screening for the disease.

"The cases that I've done have been here, at least, have been some of the most, I guess, impactful and really make me proud and happy to be a urologist and to do something [for which] the patients are incredibly grateful," says John Michael DiBianco, MD.

"We did see a rise in 2020, and that's been kind of maintained in 2021 and 2022, but overall, it looked like a pretty low rate," says Brian R. Lane, MD, PhD, FACS.

"My goal in the trip was not to see how many patients I could operate on, how many doctors I could train, [it was] to help 1 person train," says Joel Gelman, MD.

“We get exposure and get an opportunity to work with experts in the field before we even start fellowship, so that we can develop a baseline of expertise in areas of Peyronie's disease, erectile dysfunction, infertility, and managing sexual medicine and fertility in men across the board,” says Jacob Rust, MD.

"A surprise finding was the increase in opioid fulfillment beyond the 7-day postoperative period, which was really unexpected," says Laura Gressler, MS, PhD.

"I think it really is going to change my practice," says Akhil Das, MD, FACS.

Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

3. Terence Friedlander, MD, provides clinical insights on factors that inform the role for androgen deprivation therapy in the treatment of patients with localized or locally advanced prostate cancer.

“Fortunately, the chemotherapy regimens that Dr. Einhorn put together in combination with the surgical approaches with Dr. Donohue really revolutionized the cure rates and the care for men with testicular cancer,” says Clint Cary, MD, MPH, MBA.

Experts discuss available therapies beyond BCG.

Experts discuss the rate of recurrence following first-line BCG therapy.

"It's the creating of things for me that drives me. Even my wife tells me, 'You are most happy when you're creating new things,' " says Steven A. Kaplan, MD.

“It's been exciting to be on the forefront of new technology and new implants to help men regain their sexual function and empower them,” says Dr. Helen L. Bernie, DO, MPH.